Anti-factor H autoantibody-associated hemolytic uremic syndrome: the earlier diagnosed and treated, the better.
Atypical hemolytic uremic syndrome (HUS) secondary to anti-factor H autoantibodies has a poor prognosis. The study by Sinha et al. of a large cohort of Indian children makes a substantial contribution to improved management of this form of HUS by showing that standardized titration of anti-factor H autoantibodies is applicable worldwide and that early treatment initiation and guidance of maintenance treatment by autoantibody titer monitoring significantly improve outcomes.
1] Department of Pediatric Nephrology, Hôpital Robert Debré, Assistance Publique-Hôpitaux de Paris, Paris, France [2] Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
Chantal
C
Loirat
1] Laboratory of Immunology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France [2] INSERM Unité Mixte de Recherche en Santé 872, Paris, France.
Véronique
V
Frémeaux-Bacchi
D001323:Autoantibodies / Q000097:blood*; D001798:Blood Proteins / Q000276:immunology*; D003180:Complement C3b Inactivator Proteins / Q000276:immunology*; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D010951:Plasma Exchange; D061665:Time-to-Treatment
D001323:Autoantibodies; D001798:Blood Proteins; C517621:CFHR1 protein, human; C105970:CFHR3 protein, human; D003180:Complement C3b Inactivator Proteins; D007166:Immunosuppressive Agents